MicroRNA 5095: A Drug Target / Disease Biomarker (G100616458)
MicroRNA 5095: A Drug Target / Disease Biomarker
MicroRNA 5095 (miRNA-5095) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to study, and recent studies have provided valuable insights into its role in these conditions.
The miRNA-5095 molecule is composed of 20-22 amino acid residues and has a unique structure that consists of a 19-amino acid tail and a single 5'-end. It is expressed in various tissues and organs, including brain, heart, liver, and pancreas, and has been shown to play a role in several biological processes, including cell growth, apoptosis, and inflammation.
One of the most significant features of miRNA-5095 is its ability to interact with other molecules and proteins. This interaction has led to the identification of several potential drug targets and biomarkers. For example, studies have shown that miRNA-5095 can interact with the protein encoded by the gene ASXL1, which is known to promote cell growth and survival. Researchers have also found that miRNA-5095 can interact with the protein encoded by the gene PDGFRA, which is known to promote tumor growth and angiogenesis.
In addition to its potential drug targets, miRNA-5095 has also been identified as a potential biomarker for several diseases. For example, studies have shown that miRNA-5095 levels are elevated in the brains of patients with Alzheimer's disease, a neurodegenerative disorder. This increase in miRNA-5095 levels has been linked to increased neurofibrillary tangles and decreased brain volume, which are hallmark symptoms of Alzheimer's disease. Additionally, miRNA-5095 has been shown to be elevated in the blood of patients with multiple sclerosis, a neuroimmune disorder, which may indicate its potential as a biomarker for this disease.
The unique structure and function of miRNA-5095 have also made it an attractive target for research into the mechanisms of disease. For example, studies have shown that miRNA-5095 can interact with the protein encoded by the gene LRP1, which is known to regulate the expression of other genes and proteins. This interaction has led to the hypothesis that miRNA-5095 may be a negative regulator of LRP1, and that its dysregulation in diseases may contribute to the development of these conditions.
In conclusion, miRNA-5095 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for several diseases. Its unique structure and function have made it an attractive target for research into the mechanisms of disease and the development of new treatments. Further studies are needed to fully understand the role of miRNA-5095 in these conditions and to develop safe and effective drugs that can target it.
Protein Name: MicroRNA 5095
The "MicroRNA 5095 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MicroRNA 5095 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MicroRNA 5096 | MicroRNA 6087 | MicroRNA 6723 | MicroRNA 7641-1 | MicroRNA 7641-2 | Microtubule-Associated Protein | MICU1 | MICU2 | MICU3 | MID1 | MID1IP1 | MID1IP1-AS1 | MID2 | MIDEAS | MIDEAS-AS1 | MIDN | MIEF1 | MIEF2 | MIEN1 | MIER1 | MIER2 | MIER3 | MIF | MIF-AS1 | MIF4GD | MIGA1 | MIGA2 | MIIP | MILIP | MILR1 | MIMT1 | MINAR1 | MINAR2 | MINCR | MINDY1 | MINDY2 | MINDY2-DT | MINDY3 | MINDY4 | Minichromosome maintenance (MCM) 2-7 helicase complex | MINK1 | MINPP1 | MIOS | MIOX | MIP | MIPEP | MIPEPP3 | MIPOL1 | MIR1-1 | MIR1-1HG | MIR1-2 | MIR100 | MIR100HG | MIR101-1 | MIR101-2 | MIR10394 | MIR10396B | MIR10399 | MIR103A1 | MIR103A2 | MIR103B1 | MIR103B2 | MIR105-1 | MIR105-2 | MIR10527 | MIR106A | MIR106B | MIR107 | MIR10A | MIR10B | MIR11181 | MIR11400 | MIR11401 | MIR1178 | MIR1179 | MIR1180 | MIR1181 | MIR1182 | MIR1183 | MIR1184-1 | MIR1184-2 | MIR1184-3 | MIR1185-1 | MIR1185-2 | MIR1193 | MIR1197 | MIR1199 | MIR1200 | MIR1202 | MIR1203 | MIR1204 | MIR1205 | MIR1206 | MIR1207 | MIR1208 | MIR12129 | MIR12135 | MIR12136 | MIR122 | MIR1224
